THIS WEBSITE USES COOKIES
We use cookies to personalise content, to provide social media features, and to analyse our traffic. By choosing 'allow all cookies', you consent to our cookies.
To find out more, read our privacy policy and cookie policy.

Abbreviations

Abbreviations

GMB

Adult glioblastoma

pHGG

Paediatric high-grade glioma

UNCAN

EU initiative for understanding cancer

MRI

Magnetic resonance imaging 

SOC

Standard of care

I/O

Immuno-oncology

TTF

Tumour treating fields

European Cancer Summit 2024

GLIOMATCH was featured at the European Cancer Summit 2024, held on 20–21 November in Brussels and online. We’re proud to support Europe’s fight against cancer by equipping clinicians with tools to match patients to the best immunotherapies and track treatment progress.

GLIOMATCH was featured at the European Cancer Summit as part of the Horizon Europe initiative, recognising its role in advancing the EU Mission on Cancer. Horizon Europe, with a €95.5 billion budget for 2021–2027, demonstrates the EU’s commitment to cancer research, including the Cancer Mission, which aims to improve the lives of 3 million people by 2030 through better prevention, diagnosis, treatment, and support for patients and families. GLIOMATCH is part of the Understanding (tumour-host) Interaction Cluster alongside other projects such as ARTURO, HIT-GLIO, MULTIR, THRIVE, and SPACETIME. These projects collaborate to identify common challenges, share best practices, and maximise the impact of their research efforts. 

Follow GLIOMATCH on LinkedIn and Facebook for more information on brain tumour research and updates on our milestones towards improving the clinical outcomes of GBM and pHGG.

More Posts

GLIOMATCH results contribute to new EIC-funded project GLIOBREAK

On International Childhood Cancer Day, GLIOMATCH highlights the urgent need for research into paediatric high-grade gliomas (pHGGs), rare and aggressive brain tumours affecting children. With a median survival of just over one year and no curative treatment available, collaborative research efforts are essential to better understand the disease, develop dedicated models, and tailor therapies that improve outcomes and quality of life for young patients and their families.

International Childhood Cancer Day 2026

On International Childhood Cancer Day, GLIOMATCH highlights the urgent need for research into paediatric high-grade gliomas (pHGGs), rare and aggressive brain tumours affecting children. With a median survival of just over one year and no curative treatment available, collaborative research efforts are essential to better understand the disease, develop dedicated models, and tailor therapies that improve outcomes and quality of life for young patients and their families.

International Day of Women and Girls in Science 2026

GLIOMATCH celebrates the women researchers across its consortium whose expertise and commitment drive the development of tailored immunotherapies for malignant brain tumours, marking the International Day of Women and Girls in Science 2026.

World Cancer Day 2026

On World Cancer Day 2026, GLIOMATCH highlights the importance of placing patient perspectives at the heart of cancer research, particularly for glioblastoma, one of the most aggressive and difficult-to-treat brain tumours.